Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 4th Global summit on Diabetes and Endocrinology Madrid, Spain.

Day 1 :

  • Diabetes and Cardiovascular Diseases | Complication and management of diabetes | Thyroid disorders

Session Introduction

Simona Opris

National Institute of Gerontology and Geriatrics "Ana Aslan", Romania

Title: Gender-related differencies in atherogenic status and cardiovascular risk at type 2 diabetes mellitus patients

Simona Opris - Senior Scientific Researcher and Medical Principal Biochemist- expertise in biology of aging. Research fields: correlation of different biochemical mechanisms-oxidative stress implications in normal and pathological aging; immunological investigation methods by ELISA; elucidation of induce age-modifications at cardiovascular pathology; assessment criterion of biological age by identification of some specific biological markers. She published 82 scientific papers (68 first author) in national and international scientific journals (ISI-13), 159 international congresses participation and 60 national congresses, 8 national research programs. Also, Editor Assistant at Romanian Journal of Gerontology and Geriatrics, member of OBBCSR and member of Romanian Society of Gerontology and Geriatrics.



Statement of the Problem: The incidence of cardiovascular disease among patients with type 2 diabetes mellitus (DM) is high. Epidemiologic data have indicated that women are relatively spared from coronary heart disease, but after the menopause, dyslipidemia is highly prevalent in them, too. The objective of the study was to determine gender-related changes in atherogenic status and cardiovascular risk at DM patients. Methodology: Observational cross-sectional study was conducted among 91 patients with DM (over 65 years), 27 men vs. 64 women. Atherogenic index (AI) was calculated as log (triglyceride/HDL-cholesterol) and cardiovascular risk was computed as HeartScore from an assessment risk system. Findings: Study revealed a significant increased of HeartScore at men vs. women (6.66±3.9 vs. 3.2±1.51; p<0.0001). Compared to women, high risk AI is increased in men patients (74.07% vs. 71.87%). The prevalence of dyslipidemia at men patients increased from 18.51% in the low risk AI group to 74.07% in the high risk AI group. Likewise, high risk HeartScore is increased in men vs. women (77.77% vs. 12.5%). We also noticed that almost 50% from all DM patients are obese. Conclusion & Significance: Dyslipidemia in DM men patients could be an indicator of their susceptibility to cardiovascular diseases. Estrogen decline significantly alters lipid profile and increases atherogenic and cardiovascular risk. Nevertheless, men gender is associated with a more atherogenic profile, explaining the increased risk of cardiovascular diseases. Both HeartScore and AI could be used for identifying high risk in the clinical practices.


Piyarat Parklug

Department of Nuclear Medicine Radiology, Faculty of medicine, Vajira hospital, Navamindradhiraj University, Thailand

Title: Outcome of using equation for prediction of 24-hour thyroid uptake, first and second therapeutic doses calculation in Graves’ disease patients

Piyarat Parklug is nuclear medicine radiologist at Faculty of Medicine, Vajira hospital, Navamindradhiraj university for over 20 years. She is the director and instructor of nuclear medicine department of the Vajira hospital for over 10 years. Her research interest are focused on radioactive iodine treatment of hyperthyroid and Bone mineral density. She is an advisor of the nuclear medicine research in Navamindradhiraj university. She is the coordinator of drone in emergency medicine project.      


Background: The Radioactive Iodine Thyroid Uptake (RAIU) is used in calculation the I-131 treatment dose for Graves’ disease. The duration time for the standard RAIU is 24-hours, then the patient is required to visit hospital in 2 consecutive days.  Equation is the alternative method which applies 3-hours RAIU to predict 24-hours RAIU.  Thus, we can reduce duration of the study time. Objective: The study aims to evaluate the correlation between the I-131 treatment doses that calculated by Predictive 24-hours RAIU (P24U) from equation and treatment dose that calculated by actual 24-hour RAIU. The study was performed in both the first and the second Therapeutic Doses (TD) in Graves’ disease. Methods: A retrospective study was performed in Graves’ disease patients who underwent thyroid uptake and radioactive iodine treatment. Two groups were identified as the first and the second therapeutic doses. For each group, predictive value of 24-hours RAIU was calculated the equation. The equation is 24-hour RAIU = 32.5 + (0.702 × 3-hour RAIU).   The TD and PTD were calculated and compared. Results: The patients with the first therapeutic doses are 92 and the second therapeutic doses are 36. The first therapeutic dose, the correlation between 24U and P24U is 0.902 and the second therapeutic doses, the correlation between 24U and P24U is 0.806. The correlations between TD and PTD in the first and second therapeutic doses are 0.954 and 0.953 respectively. The mean difference between TD and PTD of the first and second therapeutic doses are less than 1 millicuries (-0.3 to -0.5), there is no statistically significant difference in both groups. Conclusions: The equation is an alternative method to calculate I-131 dose for Graves’ disease patients in the first and second therapeutic doses. 

Syed Ishrat Ali Kazmi

Pharmaceutical Sales & Marketing, Pakistan

Title: Diabetes Disorder, Its Prevention & Treatment

Ishrat Kazmi is a Marketer & Trainer by profession, working in a pharmaceutical company in Pakistan. He has more than 30 years of experience in pharmaceutical organizations, while he has more than a decade of experience in dealing with the Marketing of world-renowned anti-diabetics like Glucophage and Glucovance. During his association with the anti-diabetics, he worked hard to spread awareness of Pre-Diabetes, Do’s & Don’ts of Diabetes, in this context he traveled all over Pakistan with eminent Diabetologists & Endocrinologists of Pakistan, namely Dr. A. Samad Shera (late), Prof. Dr. Abdul Basit, Prof. Dr. Shabeen Naz, Dr. Ahmed Shuja, Prof. Naeem Afzal  



The term Diabetes Mellitus comes from the Greek word "Diabetes" (to siphon or pass through) and the Latin word "Mellitus" (honey or sweet). Diabetes Mellitus is a Metabolic Disorder.

Over 3,000 years ago, the ancient Egyptians mentioned a condition that appears to have been type 1 diabetes. It featured excessive urination, thirst, and weight loss.

In ancient India, people discovered that they could use ants to test for diabetes by presenting urine to them. If the ants came to the urine, this was a sign that it contained high sugar levels. They called the condition “madhumeha”, meaning honey urine.

During the third century B.C.E., Apollonius of Memphis mentioned the term "diabetes," which may have been its earliest reference.

In 1776, Matthew Dobson confirmed that the urine of people with diabetes could have a sweet taste. According to an article that the journal Medical Observations and Enquiries published, he measured the glucose in urine and found that it was high in people with diabetes.

Diabetes is a metabolic disorder, which is characterized by persistently high blood glucose, either due to lack of Insulin or due to Insulin Resistance, or both. Factors, responsible for causing Diabetes can be listed as:

  • Genes/Family History

  • Obesity

  • Stress

  • Sedentary Lifestyle

Symptoms of Diabetes are Polyuria, Polyphagia, Polydypsia, Blurred vision, Sudden weight loss, and feeling tired and less energetic.

Prevalence of Diabetes (IDF Atlas 10th Ed. 2021):

World Diabetic Population:
537 Million (20-79 years)

Types of Diabetes:

  • Pre-Diabetes

  • Type – I Diabetes

  • Type–IIII Diabetes

  • Gestational Diabetes


Prediabetes is a condition in which blood glucose levels are higher than normal but not high enough for a diagnosis of diabetes. Prediabetes is also called impaired glucose tolerance (IGT) or impaired fasting glucose (IFG), depending on the test used to measure blood glucose levels. Having prediabetes puts one at higher risk for developing type 2 diabetes. People with prediabetes are also at increased risk for developing cardiovascular disease.

Who should be tested for Pre-Diabetes and Diabetes?

The American Diabetes Association recommends that testing to detect prediabetes and type 2 diabetes be considered in adults without symptoms who are overweight or obese and have one or more additional risk factors for diabetes. In those without these risk factors, testing should begin at age 45.

Risk factors for prediabetes and diabetes in addition to being overweight or obese or being age 45 or older-include the following:

  • being physically inactive

  • having a parent, brother, or sister with diabetes

  • having a family background that is African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, or Pacific Islander

  • giving birth to a baby weighing more than 9 pounds or being diagnosed with gestational diabetes-diabetes first found during pregnancy

  • having high blood pressure-140/90 mmHg or above-or being treated for high blood pressure

  • having HDL, or "good," cholesterol below 35 mg/dL, or a triglyceride level above 250 mg/dL

  • having polycystic ovary syndrome, also called PCOS

  • having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) on previous testing

  • having other conditions associated with insulin resistance, such as severe obesity or a condition called acanthosis nigricans, characterized by a dark, velvety rash around the neck or armpits

  • having a history of cardiovascular disease

If the results of testing are normal, testing should be repeated at least every 3 years. Doctors may recommend more frequent testing depending on initial results and risk status.

Diabetes Prevention Program (DPP)

The DPP found that participants who lost a modest amount of weight through dietary changes and increased physical activity sharply reduced their chances of developing diabetes. Taking metformin also reduced risk, although less dramatically. The DPP resolved its research questions earlier than projected and, following the recommendation of an external monitoring board, the study was halted a year early. The researchers published their findings in the February 7, 2002, issue of the New England Journal of Medicine.

Diagnostic Criteria (ADA 2019)

Complications of Diabetes:

The complications of Diabetes can be divided into 2 groups i.e.

  • Micro-Vascular Complications

  • Macro-Vascular Complications



  • Diet

  • Exercise

  • Insulins

  • Oral Anti-Diabetics

  • Biguanides (Metformin)

  • Sulphonylureas Plain

  • Sulphonylureas Combinations

  • DPP IV Inhibitors Plain

  • DPP IV Inhibitors Combinations

  • Glitazones

  • SGLT2 Inhibitors Plain

  • SGLT2 Inhibitors Combinations

  • Glinides

  • A-Glucosidase Inh

  • GLP-I agonist

Advanced Treatment Options:

  • Once a Week Tablet

  • Artificial Pancreas

  • Continuous Glucose Monitoring

Continuous Glucose Monitoring (CGM) gives you a more complete picture of your glucose levels, which can lead to better lifestyle decisions and better glucose control.

A continuous glucose monitor is a small device that you wear just under your skin. It measures your glucose (sugar) levels continuously throughout the day and night, letting you see trends in your levels and alerting you to highs and lows. 


  • Others

Session Introduction

Wetchayan Chansarn

Department of Orthopaedics, Faculty of Medicine, Vajira hospital, Navamindradhiraj University, Thailand

Title: Associating Factors of Osteoporosis in post-menopausal women at Vajira Hospital, Thailand

Wetchayan Chansarn is a musculoskeletal oncology orthopaedist at Faculty of Medicine, Vajira hospital, Navamindradhiraj university. He is the instructor of Orthopaedics department of the Vajira hospital for over 3 years. His research interest focuses on bone and soft tissue cancer treatment and metabolic bone disease. He is a Committee of Musculoskeletal Oncology and a Committee of Metabolic Bone Disease and Orthogeriatics of Royal College of Orthopaedics Surgeon Thailand.   


Background and objective: Prevalence of postmenopausal osteoporosis is increasing. Osteoporosis increases the chance of fractures which increased morbidity and mortality rates. This study aims to study 3 risk factors for osteoporosis; age, body mass index, age at menopause. Methods: This cross-sectional study in postmenopausal women was evaluated for bone mineral density using Dual energy X-ray absorptiometry at nuclear medicine department in Vajira Hospital from January 2021 to December 2021. A total of 1,201 women were enrolled, 494 with osteoporosis and 707 without osteoporosis. We use criteria for the diagnosis of osteoporosis according to WHO criteria. The baseline data and risk factors; age, body mass index (BMI), and menopause age, were collected from DXA. Results: From total 1,201 populations, the mean age was 69.81 + 9.11, mean menopausal age was 48.34 + 5.69 and mean BMI was 24.98 + 4.78. In the Adjust Odds ratio analysis, the age groups 60-69, 70-79 and 80 more at risk of developing osteoporosis than 1.830, 2.687 and 6.028 times, respectively, compared to the reference age group of 50-59 years old. The underweight group and normal group have higher risk of developing osteoporosis were 5.467, 2.002 times, respectively, compared to the reference overweight group. The later menopause age in every 1 year, the lower risk of osteoporosis by 2.3 percent. Conclusion: Advance age, low BMI and menopausal age are statistically significant associated factors with the occurrence of osteoporosis in postmenopausal women.